Attached files
file | filename |
---|---|
8-K - 8-K - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | pacb-20150203x8k.htm |
EX-10.1 - EX-10.1 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | pacb-20150203ex101dd6fcb.htm |
EX-99.2 - EX-99.2 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | pacb-20150203ex992dbbecb.htm |
EX-5.1 - EX-5.1 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | pacb-20150203ex515ba49c2.htm |
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Consolidated Balance Sheets
(unaudited)
December 31, |
|||||
(in thousands, except per share amounts) |
2014 |
2013 |
|||
Assets |
|||||
Current assets |
|||||
Cash and cash equivalents |
$ |
36,449 |
$ |
26,362 | |
Investments |
64,899 | 86,166 | |||
Accounts receivable |
3,406 | 2,746 | |||
Inventory, net |
11,335 | 10,050 | |||
Prepaid expenses and other current assets |
1,671 | 1,135 | |||
Total current assets |
117,760 | 126,459 | |||
Property and equipment, net |
6,601 | 9,236 | |||
Other long-term assets |
162 | 490 | |||
Total assets |
$ |
124,523 |
$ |
136,185 | |
Liabilities and Stockholders’ Equity |
|||||
Current liabilities |
|||||
Accounts payable |
$ |
5,608 |
$ |
1,717 | |
Accrued expenses |
11,441 | 7,905 | |||
Deferred service revenue, current |
6,121 | 4,046 | |||
Deferred contractual revenue, current |
6,785 | 6,785 | |||
Other liabilities, current |
1,534 | 2,102 | |||
Total current liabilities |
31,489 | 22,555 | |||
Deferred service revenue, non-current |
1,129 | 518 | |||
Deferred contractual revenue, non-current |
19,735 | 26,519 | |||
Other liabilities, non-current |
2,153 | 3,517 | |||
Notes payable |
14,124 | 13,347 | |||
Financing derivative |
944 | 549 | |||
Total liabilities |
69,574 | 67,005 | |||
Commitments and contingencies |
|||||
Stockholders’ equity |
|||||
Preferred Stock, $0.001 par value: |
|||||
Authorized 50,000 shares; No shares issued or outstanding |
— |
— |
|||
Common Stock, $0.001 par value: |
|||||
Authorized 1,000,000 shares; Issued and outstanding 73,927 and 66,275 shares at December 31, 2014 and 2013, respectively |
74 | 66 | |||
Additional paid-in-capital |
736,339 | 684,413 | |||
Accumulated other comprehensive income |
9 | 14 | |||
Accumulated deficit |
(681,473) | (615,313) | |||
Total stockholders’ equity |
54,949 | 69,180 | |||
Total liabilities and stockholders’ equity |
$ |
124,523 |
$ |
136,185 |
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Consolidated Statements of Operations and Comprehensive Loss
(unaudited)
Years ended December 31, |
||||||||
(in thousands, except per share amounts) |
2014 |
2013 |
2012 |
|||||
Revenue: |
||||||||
Product revenue |
$ |
35,299 |
$ |
20,039 |
$ |
20,089 | ||
Service and other revenue |
8,511 | 6,446 | 5,894 | |||||
Contractual revenue |
16,784 | 1,696 |
— |
|||||
Total revenue |
60,594 | 28,181 | 25,983 | |||||
Cost of Revenue: |
||||||||
Cost of product revenue |
29,626 | 15,706 | 18,796 | |||||
Cost of service and other revenue |
7,566 | 6,056 | 6,247 | |||||
Total cost of revenue |
37,192 | 21,762 | 25,043 | |||||
Gross profit |
23,402 | 6,419 | 940 | |||||
Operating Expense: |
||||||||
Research and development |
48,230 | 45,217 | 47,623 | |||||
Sales, general and administrative |
38,026 | 38,745 | 47,655 | |||||
Total operating expense |
86,256 | 83,962 | 95,278 | |||||
Operating loss |
(62,854) | (77,543) | (94,338) | |||||
Interest expense |
(2,828) | (2,478) | (274) | |||||
Other income (expense), net |
(478) | 728 | 147 | |||||
Net loss |
(66,160) | (79,293) | (94,465) | |||||
Other comprehensive loss: |
||||||||
Unrealized loss on investments |
(5) | (16) | (27) | |||||
Comprehensive loss |
$ |
(66,165) |
$ |
(79,309) |
$ |
(94,492) | ||
Net loss per share: |
||||||||
Basic and diluted net loss per share |
$ |
(0.94) |
$ |
(1.26) |
$ |
(1.69) | ||
Shares used in computing basic and diluted net loss per share |
|
70,475 |
|
|
62,784 |
|
|
55,733 |
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Consolidated Statements of Cash Flows
(unaudited)
Years Ended December 31, |
||||||||
(in thousands) |
2014 |
2013 |
2012 |
|||||
Cash flows from operating activities |
||||||||
Net loss |
$ |
(66,160) |
$ |
(79,293) |
$ |
(94,465) | ||
Adjustments to reconcile net loss to net cash used in operating activities |
||||||||
Depreciation and amortization |
4,221 | 5,648 | 6,649 | |||||
Amortization of debt discount and financing costs |
793 | 595 |
— |
|||||
Stock-based compensation |
9,943 | 9,905 | 9,705 | |||||
Other items |
507 | (352) | 1,295 | |||||
Changes in assets and liabilities |
||||||||
Accounts receivable |
(660) | 76 | 1,735 | |||||
Inventory |
(1,285) | (60) | 4,761 | |||||
Prepaid expenses and other assets |
(224) | 840 | 50 | |||||
Accounts payable |
3,891 | (1,271) | (1,754) | |||||
Accrued expenses |
3,536 | 1,327 | (1,333) | |||||
Deferred service revenue |
2,686 | 386 | (1,674) | |||||
Deferred contractual revenue |
(6,784) | 33,304 |
— |
|||||
Other liabilities |
(1,932) | (938) | (1,791) | |||||
Net cash used in operating activities |
(51,468) | (29,833) | (76,822) | |||||
Cash flows from investing activities |
||||||||
Purchase of property and equipment |
(1,609) | (909) | (1,703) | |||||
Purchase of investments |
(126,413) | (201,547) | (87,889) | |||||
Sales of investments |
— |
100 | 7,896 | |||||
Maturities of investments |
147,586 | 169,239 | 143,488 | |||||
Net cash provided by (used in) investing activities |
19,564 | (33,117) | 61,792 | |||||
Cash flows from financing activities |
||||||||
Proceeds from issuance of common stock from equity plans |
3,968 | 3,079 | 2,705 | |||||
Proceeds from issuance of common stock from at-the-market equity offering, net of issuance costs |
38,023 | 19,927 |
— |
|||||
Proceeds from issuance of debt agreement, net of issuance costs |
— |
19,766 |
— |
|||||
Net cash provided by financing activities |
41,991 | 42,772 | 2,705 | |||||
Net increase (decrease) in cash and cash equivalents |
10,087 | (20,178) | (12,325) | |||||
Cash and cash equivalents at beginning of period |
26,362 | 46,540 | 58,865 | |||||
Cash and cash equivalents at end of period |
$ |
36,449 |
$ |
26,362 |
$ |
46,540 | ||
Supplemental disclosure of cash flow information |
||||||||
Interest paid |
$ |
1,342 |
$ |
1,165 |
$ |
— |
||
Supplemental disclosure of non-cash investing and financing activities |
||||||||
Inventory transferred to (from) property and equipment for internal use |
— |
(558) | 1,164 |